UroGen Pharma Ltd. Share Price & Technical Analysis
URGN · $28.89 (-3.31%)
Healthcare / Biotechnology
$28.89
-3.31%
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder …
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
22% return in May, -28% avg return in past 3 year May month.
30% return in 2026, 104% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -17% | 11% | -17% | 31% | 22% | – | – | – | – | – | – | – | 30% |
| 25 | 2% | -12% | 17% | 5% | -63% | 211% | 38% | 5% | 3% | 4% | 40% | -17% | 234% |
| 24 | 5% | 16% | -13% | -7% | -6% | 24% | -2% | -16% | -8% | -2% | 3% | -17% | -23% |
| 23 | 17% | -1% | -12% | 26% | -15% | 5% | 109% | -19% | -22% | -20% | 19% | 14% | 100% |
| 22 | -20% | -22% | 45% | -18% | -25% | 52% | -5% | -5% | 11% | 40% | -28% | 5% | 28% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.45B
P/E ratio
—
52W high
$32.37
52W low
$3.60
Volume
3,64,372
Beta
1.59
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is UroGen Pharma Ltd. share price today?
- UroGen Pharma Ltd. (URGN) last traded around $28.89 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does URGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for URGN. Download the app for real-time alerts.
- How can I analyze UroGen Pharma Ltd. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.